This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
H-Ras is a unique isoform of the Ras GTPase family, one of the most prominently mutated oncogene families across the cancer landscape. Relative to other isoforms, though, mutations of H-Ras account for the smallest proportion of mutant Ras cancers. Yet, in recent years, there have been renewed efforts to study this isoform, especially as certain H-Ras–driven cancers, like those of the head and neck, have become more prominent. Important advances have therefore been made not only in the understanding of H-Ras structural biology but also in approaches designed to inhibit and impair its signaling activity. In this review, we outline historic and present initiatives to elucidate the mechanisms of H-Ras–dependent tumorigenesis as well as highlight ongoing developments in the quest to target this critical oncogene.
This article is featured in Highlights of This Issue, p. 973
Footnotes
Mol Cancer Ther 2020;19:999–1007
- Received July 17, 2019.
- Revision received December 2, 2019.
- Accepted January 14, 2020.
- Published first April 1, 2020.
- ©2020 American Association for Cancer Research.